Mirvetuximab soravtansine

{
  "id": "MLC-T-ONC-005403",
  "term": "Mirvetuximab soravtansine",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with folate receptor alpha-positive ovarian epithelial, fallopian tube, or primary peritoneal cancer that has not gotten better after treatment with platinum chemotherapy. It is used in patients whose cancer was treated with one to three other systemic therapies. It is also being studied in the treatment of other types of cancer. Mirvetuximab soravtansine contains a monoclonal antibody that binds to a protein called folate receptor alpha, which is found on some cancer cells. It also contains an anticancer drug, which may help kill cancer cells. Mirvetuximab soravtansine is a type of antibody-drug conjugate. Also called Elahere.",
    "An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agent's efficacy in multidrug resistant tumor cells."
  ],
  "synonyms": [
    "Elahere",
    "M9346A-sulfo-SPDB-DM4",
    "mirvetuximab Soravtansine-gynx"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/mirvetuximab-soravtansine/"
}